| Literature DB >> 23469029 |
Maria A De Marco1, Stefano Porru, Paolo Cordioli, Bruno M Cesana, Ana Moreno, Laura Calzoletti, Lebana Bonfanti, Arianna Boni, Antonio Scotto Di Carlo, Cecilia Arici, Angela Carta, Maria R Castrucci, Isabella Donatelli, Paola Tomao, Vittoria M Peri, Livia Di Trani, Nicoletta Vonesch.
Abstract
BACKGROUND: Pigs play a key epidemiologic role in the ecology of influenza A viruses (IAVs) emerging from animal hosts and transmitted to humans. Between 2008 and 2010, we investigated the health risk of occupational exposure to swine influenza viruses (SIVs) in Italy, during the emergence and spread of the 2009 H1N1 pandemic (H1N1pdm) virus. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2013 PMID: 23469029 PMCID: PMC3585202 DOI: 10.1371/journal.pone.0057576
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the swine worker and control groups.
| Variable | Subcategory | Study period | ||||||
| Pre-pandemic peak | Post-pandemic peak | Total | ||||||
| SWs, n (%) | Cs, n (%) | SWs, n (%) | Cs, n (%) | SWs, n (%) | Cs, n (%) | |||
| 84 (68.3) | 234 (61.7) | 39 (31.7) | 145 (38.3) | 123 (100) | 379 (100) | |||
| Age | ≤40 years | 24 (28.6) | 111 (47.4) | 16 (41.0) | 85 (58.6) | 40 (32.5) | 196 (51.7) | |
| 41–50 years | 33 (39.3) | 77 (32.9) | 12 (30.8) | 38 (26.2) | 45 (36.6) | 115 (30.3) | ||
| >50 years | 27 (32.1) | 46 (19.7) | 11 (28.2) | 22 (15.2) | 38 (30.9) | 68 (17.9) | ||
| Sex | Male | 79 (94.0) | 161 (68.8) | 38 (97.4) | 129 (89.0) | 117 (95.1) | 290 (76.5) | |
| Female | 5 (6.0) | 73 (31.2) | 1 (2.6) | 16 (11.0) | 6 (4.9) | 89 (23.5) | ||
| Seasonal | Yes | 16 (19.0) | 61 (26.1) | 7 (17.9) | 27 (18.6) | 23 (18.7) | 88 (23.2) | |
| vaccine | No | 68 (81.0) | 173 (73.9) | 32 (82.1) | 118 (81.4) | 100 (81.3) | 291 (76.8) | |
Seasonal vaccine was defined as any previous vaccination against seasonal influenza.
p<0.05. The calculated p-value is referred to total numbers of swine workers (SWs) and controls (Cs).
Pandemic peak cut-off date 1 November 2009.
Swine and human influenza viruses: HI antigenic characterization of H1 strains.
| HI titer of serum against: | |||||
| Virus origin | Virus strain | A/Sw/It/114347–1/06 (H1N2) | A/Sw/It/125746/05 (H1N1) | A/Brisbane/59/07 (H1N1) | A/California/7/09 (H1N1) |
| Swine |
|
| <10 | <10 | <10 |
| Swine | A/Sw/It/125746/05, H1N1 | <10 |
| 10 | 80 |
| A/Sw/It/66732/2/06, H1N1 | <10 | 1280 | <10 | 320 | |
| A/Sw/It/87491/06, H1N1 | <10 | 1280 | <10 | 160 | |
| A/Sw/It/45894/2/07, H1N1 | <10 | 640 | <10 | 160 | |
| A/Sw/It/68030/07, H1N1 | <10 | 640 | <10 | 160 | |
| A/Sw/It/232868/07, H1N1 | <10 | 1280 | <10 | 320 | |
| A/Sw/It/207871/08, H1N1 | <10 | 640 | <10 | 160 | |
|
| <10 | 640 | <10 | 160 | |
| Human |
| 10 | 20 |
| <10 |
|
| <10 | 160 | <10 |
| |
HI, Haemagglutination inhibition.
Chicken hyperimmune antiserum.
Ferret post-infection antiserum.
Virus strains used to test swine workers’ and controls’ sera are underlined.
SIVs strains isolated from pigs, in the farms under study.
Swine and human influenza viruses: HI antigenic characterization of H3 strains.
| HI titer of serum against: | |||
| Virus origin | Virus strain | A/Sw/It/79604/06 (H3N2) | A/Brisbane/10/07 (H3N2) |
| Swine | A/Sw/It/79604/06, H3N2 |
| <10 |
|
| 1280 | <10 | |
| A/Sw/It/20319/06, H3N2 | 1280 | <10 | |
| A/Sw/It/186423/07, H3N2 | 640 | <10 | |
| A/Sw/It/206453/07, H3N2 | 1280 | <10 | |
| A/Sw/It/319388/07, H3N2 | 1280 | <10 | |
| A/Sw/It/209720/08, H3N2 | 1280 | <10 | |
| A/Sw/It/136775/08, H3N2 | 1280 | <10 | |
| A/Sw/It/120014/08, H3N2 | 1280 | <10 | |
| A/Sw/It/117304/08, H3N2 | 640 | <10 | |
| A/Sw/It/235509/08, H3N2 | 640 | <10 | |
| Human |
| <10 |
|
HI, Haemagglutination inhibition.
Chicken hyperimmune antiserum.
Virus strains used to test swine workers’ and controls’ sera are underlined.
SIVs strains isolated from pigs, in the farms under study.
HI antibody reactivity of SWs and Cs sera against swine and human influenza viruses during the whole study period (Italy, 2008–2010)§.
| Virus | Cutoff value | SWs, N = 123 | Cs, N = 379 | Unadjusted OR | Adjusted OR |
| n (%) | n (%) | (95% CI) | (95% CI) | ||
| swH1N1 | ≥10 | 67 (54.5) | 25 (6.6) | 16.9 (9.9–29.0)*** | 17.2 (2.3–0.2)*** |
| ≥20 | 39 (31.7) | 13 (3.4) | 13.1 (6.7–25.6)*** | 12.3 (6.3–25.0)*** | |
| ≥40 | 14 (11.4) | 7 (1.8) | 6.8 (2.7–17.3)*** | 6.6 (2.5–17.4)*** | |
| huH1N1pdm | ≥10 | 72 (58.5) | 64 (16.9) | 6.9 (4.4–10.9)*** | 7.3 (4.6–12.6)*** |
| ≥20 | 62 (50.4) | 45 (11.9) | 7.5 (4.7–12.1)*** | 7.6 (4.7–12.4)*** | |
| ≥40 | 39 (31.7) | 32 (8.4) | 5.0 (3.0–8.5)*** | 5.3 (3.1–9.2)*** | |
| swH1N2 | ≥10 | 41 (33.3) | 153 (40.4) | 0.7 (0.5–1.1) | 0.7 (0.5–1.1) |
| ≥20 | 30 (24.4) | 93 (24.5) | 1.0 (0.6–1.6) | 1.0 (0.6–1.7) | |
| ≥40 | 19 (15.4) | 44 (11.6) | 1.4 (0.8–2.5) | 1.5 (0.8–2.8) | |
| huH1N1 | ≥10 | 58 (47.2) | 228 (60.2) | 0.6 (0.4–0.9)** | 0.6 (0.4–0.9)** |
| ≥20 | 45 (36.6) | 193 (50.9) | 0.6 (0.4–0.8)** | 0.6 (0.4–0.9)** | |
| ≥40 | 35 (28.5) | 150 (39.6) | 0.8 (0.4 –1.4) | nc | |
| swH3N2 | ≥10 | 63 (51.2) | 210 (55.4) | 0.8 (0.6–1.3) | 0.8 (0.5–1.3) |
| ≥20 | 49 (39.8) | 161 (42.5) | 0.9 (0.6–1.4) | 1 (0.6–1.4) | |
| ≥40 | 34 (27.6) | 110 (29.0) | 0.9 (0.6–1.5) | 0.9 (0.6–1.5) | |
| huH3N2 | ≥10 | 51 (41.5) | 218 (57.5) | 0.5 (0.3–0.8)** | 0.8 (0.6–1.3)** |
| ≥20 | 43 (35.0) | 188 (49.6) | 0.5 (0.4–0.8)** | 0.9 (0.6–1.4)** | |
| ≥40 | 35 (28.5) | 147 (38.8) | 0.6 (0.4–0.1)* | 1 (0.6–1.6)* |
Values are no. persons with antibodies.
Data adjusted by age in binary logistic regression.
HI, Haemagglutination inhibition.
SWs, swine workers; Cs, controls.
OR, odds ratio; CI, confidence interval; nc, not calculated.
swH1N1, A/Swine/Italy/44795/08; huH1N1pdm, A/California/7/09;
swH1N2, A/Swine/Italy/114347–1/06; huH1N1, A/Brisbane/59/07;
swH3N2, A/Swine/Italy/32242/06; huH3N2, A/Uruguay/716/07.
Statistically significant values: *, p<0.05; **, p<0.01; ***, p<0.001.
SWs and Cs sera collected before and after the 2009 pandemic influenza peak: HI antibody reactivity against swH1N1 and H1N1pdm viruses§.
| Virus | Cutoff value | Pre-pandemic peak period | Post-pandemic peak period | ||||
| (15 Dec. 2008–1 Nov. 2009) | (2 Nov. 2009–3 Oct. 2010) | ||||||
| SWs | Cs | SWs | Cs | ||||
| N = 84 | N = 234 | OR | N = 39 | N = 145 | OR | ||
| n (%) | n (%) | (95% CI) | n (%) | n (%) | (95% CI) | ||
| swH1N1 | ≥10 | 44 | 11 | 22.2 | 23 | 14 | 13.6 |
| (52.4) | (4.7) | (10.6–46.6)*** | (59.0) | (9.7) | (5.8–31.5)*** | ||
| ≥20 | 26 | 4 | 25.7 | 13 | 9 | 7.6 | |
| (31.0) | (1.7) | (8.6–76.4)*** | (33.3) | (6.2) | (2.9–19.7)*** | ||
| ≥40 | 11 | 2 | 17.4 | 3 | 5 | 2.3 | |
| (13.1) | (0.9) | (3.8–80.3)*** | (7.7) | (3.4) | (0.5–10.3) | ||
| huH1N1pdm | ≥10 | 49 | 18 | 16.7 | 23 | 46 | 3.1 |
| (58.3) | (7.7) | (8.7–32)*** | (59) | (31.7) | (1.5–6.5)** | ||
| ≥20 | 42 | 15 | 14.5 | 20 | 30 | 4.1 | |
| (50.0) | (6.4) | (7.4–28.6)*** | (51.3) | (20.7) | (1.9–8.6)*** | ||
| ≥40 | 24 | 11 | 8.1 | 15 | 21 | 3.7 | |
| (28.6) | (4.7) | (3.7–17.4)*** | (38.5) | (14.5) | (1.6–8.2)** | ||
Values are no. persons with antibodies.
SWs, swine workers; Cs, controls; OR, odds ratio; CI, confidence interval.
swH1N1,/Swine/Italy/44795/08; huH1N1pdm, A/California/7/09.
Statistically significant values: *, p<0.05; **, p<0.01; ***, p<0.001.
Figure 1HI antibody reactivity against swH1N1 and H1N1pdm viruses in SWs (Italy, 2008–2010).
Serum samples were collected from swine workers (SWs) in the pre-pandemic peak (15 December 2008–1 November 2009) and post-pandemic peak (2 November 2009–3 October 2010) periods and tested by haemagglutination inhibition (HI) assay. Individual HI results referred to the three cutoff levels (≥10, ≥20 and ≥40) chosen for the statistical analysis of data, and ranging from 10 (minimum level of detection) to 40 (protective antibody titer). No significant difference in seroprevalence rate (SPR) was found in SWs sera tested by HI assay against swH1N1 (Figure 1A) and H1N1pdm (Figure 1B) viruses (viruses details and SPRs are shown in Table 5).
Figure 2HI antibody reactivity against swH1N1 and H1N1pdm viruses in Cs (Italy, 2008–2010).
Serum samples were collected from control subjects (Cs) in the pre-pandemic peak (15 December 2008–1 November 2009) and post-pandemic peak (2 November 2009–3 October 2010) periods and tested by haemagglutination inhibition (HI) assay. Individual HI results referred to the three cutoff levels (≥10, ≥20 and ≥40) chosen for the statistical analysis of data, and ranging from 10 (minimum level of detection) to 40 (protective antibody titer). A significant increase in seroprevalence rate (SPR) was found against swH1N1 at cutoff ≥20 (Figure 2A), whereas H1N1pdm SPRs (Figure 2B) were significantly higher in the post-pandemic peak period, at all cutoff titer levels (viruses details and SPRs are shown in Table 5). SPR significant difference (p<0.05).